PSTV — Plus Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $6.84m
- $5.34m
- $4.91m
- 25
- 30
- 33
- 19
Annual income statement for Plus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7 | 0.303 | 0 | 0.224 | 4.91 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 10.7 | 9.89 | 12.5 | 19.9 | 18.2 |
| Operating Profit | -3.66 | -9.58 | -12.5 | -19.7 | -13.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.28 | -8.24 | -13.4 | -20.3 | -13.3 |
| Net Income After Taxes | -3.28 | -8.24 | -13.4 | -20.3 | -13.3 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -10.9 | -8.24 | -13.4 | -20.3 | -13.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11.4 | -8.24 | -13.4 | -20.3 | -13.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -41.6 | -25.3 | -16.2 | -11.6 | -4.24 |